1. Inclusion criteria : Patients newly diagnosed with mantle cell lymphoma by a pathologist (based on the 2016 revision of the WHO classification) 1) mantle cell lymphoma 2) leukemic non-nodal mantle cell lymphoma 3) in situ mantle cell neoplasia
2. Age ≥ 19 years
3. Patients who received bendamustine + rituximab as initial therapy and patients who received bendamustine + rituximab for the treatment of relapsed/refractory condition are both included.
2\. Exclusion criteria :
1. Patients whose clinical and pathological data are not available
2. Patients who were not treated with a combination of bendamustine and rituximab
Data of patients who received bendamustine + rituximab for relapsed/refractory mantle cell lymphoma collected before the date of first submission of an IRB application for new project will be analyzed.
The aim is to publish the data analysis and study results before December 2020. The expected overall study period is until December 2020.
Age
19–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1\. Patients newly diagnosed with mantle cell lymphoma by a pathologist (based on the 2016 revision of the WHO classification)
1. mantle cell lymphoma
2. leukemic non-nodal mantle cell lymphoma
3. in situ mantle cell neoplasia 2. Age ≥ 19 years 3. Patients who received bendamustine + rituximab as initial therapy and patients who received bendamustine + rituximab for the treatment of relapsed/refractory condition are both included.
You may not be if
1\. Patients whose clinical and pathological data are not available 2. Patients who were not treated with a combination of bendamustine and rituximab
Clareo Health | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
